GELSOMINO, FRANCESCO

GELSOMINO, FRANCESCO  

DIPARTIMENTO DI MEDICINA SPECIALISTICA, DIAGNOSTICA E SPERIMENTALE (attivo dal 28/10/2011 al 31/12/2022)  

Collaboratori  

Mostra records
Risultati 1 - 20 di 30 (tempo di esecuzione: 0.045 secondi).
Titolo Autore(i) Anno Periodico Editore Tipo File
Peripheral nervous system adverse events associated with immune checkpoint inhibitors Rossi S.; Gelsomino F.; Rinaldi R.; Muccioli L.; Comito F.; Di Federico A.; De Giglio A.; Lambert...i G.; Andrini E.; Mollica V.; D'Angelo R.; Baccari F.; Zenesini C.; Madia P.; Raschi E.; Cortelli P.; Ardizzoni A.; Guarino M. 2023-01-01 JOURNAL OF NEUROLOGY - 1.01 Articolo in rivista Rossi_JN_2023.pdf
Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial Grassi, E; Zingaretti, C; Petracci, E; Corbelli, J; Papiani, G; Banchelli, I; Valli, I; Frassinet...i, G L; Passardi, A; Di Bartolomeo, M; Pietrantonio, F; Gelsomino, F; Carandina, I; Banzi, M; Martella, L; Bonetti, A V; Boccaccino, A; Molinari, C; Marisi, G; Ugolini, G; Nanni, O; Tamberi, S 2023-01-01 ESMO OPEN - 1.01 Articolo in rivista main.pdf
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies Andrini E.; Di Federico A.; Sisi M.; Rosellini M.; Palladini A.; Lamberti G.; De Giglio A.; Gelso...mino F. 2022-01-01 IMMUNOTHERAPY - 1.01 Articolo in rivista -
Next-generation technologies in predictive molecular pathology of lung cancers de Biase, Dario; Maloberti, Thais; De Leo, Antonio; Sanza, Viviana; Visani, Michela; Gruppioni, E...lisa; Altimari, Annalisa; Grillini, Alessia; Gelsomino, Francesco; Ferrari, Marco; Ardizzoni, Andrea; Tallini, Giovanni 2022-01-01 Journal of Xiangya Medicine - 1.01 Articolo in rivista 8323-PB5-2020-R3.pdf
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System Sisi, Monia; Fusaroli, Michele; De Giglio, Andrea; Facchinetti, Francesco; Ardizzoni, Andrea; Ras...chi, Emanuel; Gelsomino, Francesco 2022-01-01 TARGETED ONCOLOGY - 1.01 Articolo in rivista Sisi2022_Article_PsychiatricAdverseReactionsToA.pdf11523_2021_865_MOESM1_ESM.pdf
IFN-γ and CD38 in Hyperprogressive Cancer Development Angelicola, Stefania; Ruzzi, Francesca; Landuzzi, Lorena; Scalambra, Laura; Gelsomino, Francesco;... Ardizzoni, Andrea; Nanni, Patrizia; Lollini, Pier-Luigi; Palladini, Arianna 2021-01-01 CANCERS - 1.01 Articolo in rivista CD38 cancers-13-00309-v2.pdf
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience Vitale G.; Lamberti G.; Comito F.; Di Nunno V.; Massari F.; Morelli M.C.; Ardizzoni A.; Gelsomino F. 2020-01-01 EXPERT OPINION ON BIOLOGICAL THERAPY - 1.01 Articolo in rivista -
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial) Gelsomino F.; Lamberti G.; Tiseo M.; Rocco D.; Pasello G.; Cecere F.L.; Chella A.; Grilli G.; Man...druzzato M.; Tognetto M.; Garassino M.C.; Macerelli M.; Novello S.; Roila F.; Colantonio I.; Grossi F.; Fiorentino M.; Ardizzoni A. 2020-01-01 THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY - 1.01 Articolo in rivista Gelsomino_CHANCE_TAMO'20.pdf
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma Lamberti G.; Andrini E.; Sisi M.; Rizzo A.; Parisi C.; Di Federico A.; Gelsomino F.; Ardizzoni A. 2020-01-01 CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY - 1.01 Articolo in rivista -
Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer Parisi C.; Lamberti G.; Zompatori M.; Gelsomino F.; Salvagni S.; Sperandi F.; Ardizzoni A. 2020-01-01 JOURNAL FOR IMMUNOTHERAPY OF CANCER - 1.01 Articolo in rivista Parisi_Cystic airspaces_JIC'20.pdf
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance Raschi E.; Gatti M.; Gelsomino F.; Ardizzoni A.; Poluzzi E.; De Ponti F. 2020-01-01 TARGETED ONCOLOGY - 1.01 Articolo in rivista ICI_Targeted_Oncology_2020.pdf11523_2020_738_MOESM1_ESM.pdf
New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event Lamberti G.; Gelsomino F.; Brocchi S.; Poerio A.; Melotti B.; Sperandi F.; Gargiulo M.; Borghi C....; Fiorentino M.; Ardizzoni A. 2020-01-01 THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY - 1.01 Articolo in rivista Lamberti_atheromatous plaque_TAMO'20.pdf
Overcoming Primary Resistance to PD-1 Inhibitor With Anti–PD-L1 Agent in Squamous-Cell NSCLC: Case Report Gelsomino F.; Di Federico A.; Filippini D.M.; Dall'Olio F.G.; Lamberti G.; Sperandi F.; Balacchi ...C.; Brocchi S.; Ardizzoni A. 2020-01-01 CLINICAL LUNG CANCER - 1.01 Articolo in rivista -
Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) Gelsomino F.; Tiseo M.; Barbieri F.; Riccardi F.; Cavanna L.; Frassoldati A.; Delmonte A.; Longo ...L.; Dazzi C.; Cinieri S.; Colantonio I.; Sperandi F.; Lamberti G.; Brocchi S.; Tofani L.; Boni L.; Ardizzoni A. 2020-01-01 BRITISH JOURNAL OF CANCER - 1.01 Articolo in rivista s41416-020-0845-3.pdf41416_2020_845_MOESM1_ESM.doc
Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study Ricci C.; Capizzi E.; Giunchi F.; Casolari L.; Gelsomino F.; Rihawi K.; Natali F.; Livi V.; Triso...lini R.; Fiorentino M.; Ardizzoni A. 2020-01-01 THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY - 1.01 Articolo in rivista 1758835920954802.pdf
The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players? Lamberti G.; Sisi M.; Andrini E.; Palladini A.; Giunchi F.; Lollini P.-L.; Ardizzoni A.; Gelsomin...o F. 2020-01-01 CANCERS - 1.01 Articolo in rivista Lamberti_PDL1_cancers-12-03129.pdf
Complete Recalcification Following Arterial Embolization of Massive Osteolytic Bone Metastasis From NSCLC Francesco Gelsomino,Giancarlo Facchini, Maria Aurelia Barbera,
Giuseppe Lamberti, Stefano Bro...
cchi, Giuseppe Rossi,
Andrea Ardizzoni
2019-01-01 JOURNAL OF THORACIC ONCOLOGY - 1.01 Articolo in rivista -
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC Cinausero M.; Laprovitera N.; Maglio G.D.; Gerratana L.; Riefolo M.; Macerelli M.; Fiorentino M.;... Porcellini E.; Buoro V.; Gelsomino F.; Squadrilli A.; Fasola G.; Negrini M.; Tiseo M.; Ferracin M.; Ardizzoni A. 2019-01-01 THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY - 1.01 Articolo in rivista 2019_Immunotherapy.pdf
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC Mazzaschi, Giulia; Facchinetti, Francesco; Missale, Gabriele; Canetti, Diana; Madeddu, Denise; Ze...cca, Alessandra; Veneziani, Michele; Gelsomino, Francesco; Goldoni, Matteo; Buti, Sebastiano; Bordi, Paola; Aversa, Franco; Ardizzoni, Andrea; Quaini, Federico; Tiseo, Marcello 2019-01-01 LUNG CANCER - 1.01 Articolo in rivista -
The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers Gelsomino, Francesco; Lamberti, Giuseppe; Parisi, Claudia; Casolari, Laura; Melotti, Barbara; Spe...randi, Francesca; Ardizzoni, Andrea 2019-01-01 CANCER TREATMENT REVIEWS - 1.01 Articolo in rivista -